<DOC>
	<DOCNO>NCT02895061</DOCNO>
	<brief_summary>Primary objective evaluate efficacy daily pulse oral alfacalcidol treatment SHPT chronic hemodialysis patient , 12-week treatment . Secondary objective observe adverse effect two treatment regimen .</brief_summary>
	<brief_title>Effectiveness Between Daily Versus Pulse Oral Alfacalcidol Secondary Hyperparathyroidism Chronic Hemodialysis Patients : A Randomized Controlled Trial Multicenter Study</brief_title>
	<detailed_description>ESRD patient secondary hyperparathyroidism 3 hemodialysis center enrol . They assign either oral daily pulse ( trice week ) alfacalcidol treatment use block-of-4 randomization . Alfacalcidol group equal dose 6 microgram per week . Clinical laboratory data obtain baseline monitor every 4 week 12 week . Primary outcome difference mean PTH reduction two group end study unpaired-T test . All possible adverse event carefully monitor .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>Age ≥ 18 ESRD HD KT/V ≥ 3.6/wk 2˚HPT Stable P binder 4 wk Alfacalcidol allergy Serum Ca ≥ 10.5 mg/dL Serum P ≥ 5.5 mg/dL Pregnancy On phenytoin , phenobarbital</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>